[1] 鱼小红,吴忠兰,关光玉,等.集合丙型肝炎病毒-RNA RT-PCR方法对宁夏美沙酮门诊人群丙型肝炎年发病率的预估研究.中国卫生检验杂志,2017,27:1440-1444. [2] Rezaei N, Amini-Kafiabad S, Maghsudlu M, et al. Risk factor analysis of hepatitis C virus seropositivity in Iranian blood donors: a case-control study: risk factors for HCV infection in blood donors. Transfusion, 2016, 56:1891-1898. [3] Vasudevan S, Shalimar, Kavimandan A, et al. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India.Indian J Med Res, 2016, 143:331-334. [4] 孙桂香, 吴月清, SUNGui-xiang,等.1026例输血前患者血HBsAg、抗HCV、抗HIV和梅毒抗体检测结果分析. 标记免疫分析与临床, 2015, 22:18-19. [5] 中华医学会肝病学分会, 中华医学会感染病学分会, Chinese Society of Hepatology Chinese SocietyofI,等.丙型肝炎防治指南(2015年更新版). 中华实验和临床感染病杂志(电子版), 2015, v.9:26-43. [6] Nicholas J. Simmonds. Cystic fibrosis presenting in adulthood. Clin Pulm Med, 2013, 20:1-5. [7] 付彩文,王文兰,张晓红, 等.原发性肝癌肝动脉化疗栓塞治疗前后血清血管内皮生长因子与CT灌注参数的相关性分析.肝脏,2018,23:525-528. [8] 李强, 黄玉仙, 陈良. HCV相关肝硬化抗病毒治疗现状. 临床肝胆病杂志, 2015, 31:1813-1816. [9] 曾月婷, 梁结玲, 陈洪清,等. 1200例输血前患者HBsAg、抗-HCV、抗-HIV及梅毒抗体检测的调查研究. 国际检验医学杂志, 2017, 38:2448-2450. [10] 邓浩辉,李晓强,高洪波等.HIV/HCV混合感染者与HCV感染者感染HCV基因型分析.实用肝脏病杂志,2019,22:656-659. [11] 陈旭,苏明华,江建宁, 等.广西地区HIV合并HCV感染人群HCV基因型分布特征.中国艾滋病性病,2016,22:593-596. [12] Feld JJ, Raoel M, Stefan Z, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis,63:776-783. [13] 戎霞, 郑英, 熊华平,等.广东地区临床患者和献血者HCV感染者HCV基因分型比较. 中国输血杂志, 2014, 27:593-596. [14] Jafroodi M, Davoudi-Kiakalayeh A, Mohtasham-Amiri Z, et al. Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in iran. Int J prev med, 2015, 6:89-94. [15] 刘炜,王芳,张宁, 等.119例疑似非输血感染者抗-HCV与HCV RNA检测结果比较与分析.中国卫生检验杂志,2015,25:985-987. [16] 吴静,东保吉,吴超等.慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究.实用肝脏病杂志,2019,22:192-195. [17] 许可, 鲍倡俊, 王洁,等. 江苏省丹阳市465例丙型肝炎病毒感染者自然转归及相关因素调查. 中华流行病学杂志, 2017, 38:194-199. |